Joe Jimenez

Latest Headlines

Latest Headlines

Novartis CEO outlines a winning drug development strategy

Novartis ($NVS) CEO Joe Jimenez took a minute during a recent interview with Fortune to explain the company's drug development strategy. Rather than go after a blockbuster indication, Novartis

Novartis chief continues cost-cutting drive

Novartis ($NVS) chief Joe Jimenez (photo) started slashing expenses at the drugmaker even before he took over the CEO's job. That cost-cutting has continued apace, with jobs and facilities facing the

Novartis CEO vowing to back ambitious $8B R&D strategy

While Pfizer goes about the business of dramatically reducing its R&D budget, Novartis CEO Joe Jimenez says he isn't about to go down that path. Instead, says the CEO, he intends to snip away at

Novartis chief eyes bolt-on deals up to $1B

Novartis ($NVS) CEO Joe Jimenez (photo) has a shopping list, and he's not afraid to share it. At the World Economic Forum in Davos, Jimenez chatted about his appetite for deals with the Wall Street

Jiminez: Novartis ($NVS) isn't 'giving up' on pharma model

Call it the Swiss strategy squabble. In advance of his first big public show since taking over Novartis ($NVS) as chief executive, Joe Jiminez (photo) talked strategy with the Financial Times--and

Has pharma outgrown the scientist CEO?

Is the era of the scientist-CEO over in Big Pharma? The Financial Times suggests it's so. And to hear the experts tell it, there's a reason for that. Executives with lots of commercial and marketing

Novartis CEO goes on a 'decluttering' drive

New Novartis (NYSE:NVS) chief Joe Jiminez (photo) is talking execution again. In an interview with the Financial Times, Jiminez described some of his initiatives--and they're all about the E word.

New Novartis chief talks productivity

Novartis has released more information about its U.S. drug reorganization: Andre Wyss is set to take the reins of that business, which is restructuring and cutting about 20 percent of its

Novartis eyes bolt-on deals in generics, vaccines

Now that it's done a $39.3 billion deal for Alcon, Novartis is joining the "no-megamerger" pharma fraternity. At the company's annual shareholders' meeting in Basel, Switzerland, new CEO Joe Jiminez

New Novartis chief scouting for 'bolt-on' buyouts

Newly-appointed Novartis CEO Joe Jimenez got his first chance to take the lead role at the annual shareholders' meeting today, and started to give the industry a better feel for just the kind of new